KRAS and carcinoma: In the classical path of CRC development, activating mutations in the KRAS oncogene are thought to follow aberrant WNT pathway activation (Fearon & Vogelstein, 1990); hence, the origin of the TA1 organoid culture is likely to be a more advanced adenoma or early carcinoma.